Treatment of Vasomotor Symptoms

References

1. 1.↵
   1. Williams M,
   2. Richard Davis G,
   3. Williams PL,
   4. et al

   . A review of African American women's experiences in menopause. Menopause 2022;29:1331–7.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Avis NE,
   2. Crawford SL,
   3. Green R

   . Vasomotor symptoms across the menopause transition: differences among women. Obstet Gynecol Clin North Am 2018;45:629–40.

   OpenUrlPubMed
3. 3.↵
   1. Harlow SD,
   2. Burnett-Bowie SM,
   3. Greendale GA,
   4. et al

   . Disparities in reproductive aging and midlife health between Black and White women: the Study of Women's Health Across the 262 Nation (SWAN). Womens Midlife Health 2022;8:3.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. El Khoudary SR,
   2. Greendale G,
   3. Crawford SL,
   4. et al

   . The menopause transition and women's health at midlife: a progress report from the Study of Women's Health Across the Nation (SWAN). Menopause 2019;26:1213–27.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Freeman EW,
   2. Sammel MD,
   3. Sanders RJ

   . Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause 2014;21:924–32. Sep.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Kaunitz AM,
   2. Manson JE

   . Management of menopausal symptoms. Obstet Gynecol 2015;126:859–76.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Crandall CJ,
   2. Aragaki A,
   3. Cauley JA,
   4. et al

   . Associations of menopausal vasomotor symptoms with fracture incidence. J Clin Endocrinol Metab 2015;100:524–34.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Thurston RC,
   2. Aslanidou Vlachos HE,
   3. Derby CA,
   4. et al

   . Menopausal vasomotor symptoms and risk of incident cardiovascular disease events in SWAN. J Am Heart Assoc 2021;10:e017416.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Carson MY,
   2. Thurston RC

   . Vasomotor symptoms and their links to cardiovascular disease risk. Curr Opin Endocr Metab Res 2023;30.
10. 10.↵
    1. Ryu KJ,
    2. Park H,
    3. Park JS,
    4. et al

    . Vasomotor symptoms: more than temporary menopausal symptoms. J Menopausal Med 2020;26:147–53.

    OpenUrlPubMed
11. 11.↵
    1. Nappi RE,
    2. Kroll R,
    3. Siddiqui E,
    4. et al

    . Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden. Menopause 2021;28:875–82.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Patel B,
    2. Dhillo WS

    . Menopause review: emerging treatments for menopausal symptoms. Best Pract Res Clin Obstet Gynaecol 2022;81:134–44.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Skorupskaite K,
    2. George JT,
    3. Anderson RA

    . The kisspeptin-GnRH pathway in human reproductive health and disease. Hum Reprod Update 2014;20:485–500.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Wakabayashi Y,
    2. Nakada T,
    3. Murata K,
    4. et al

    . Neurokinin B and dynorphin A in kisspeptin neurons of the arcuate nucleus participate in generation of periodic oscillation of neural activity driving pulsatile gonadotropin-releasing hormone secretion in the goat. J Neurosci 2010;30:3124–32.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause 2022;29:767–94.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Rossouw JE,
    2. Prentice RL,
    3. Manson JE,
    4. et al

    . Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–77.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    1. Manson JE,
    2. Aragaki AK,
    3. Rossouw JE

    , WHI Investigatorset al. Menopausal hormone therapy and long term all-cause and cause-specific mortality: the Women's Health Initiative Randomized Trials. JAMA 2017;318:927–38.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Mirkin S,
    2. Komm BS,
    3. Pan K,
    4. Chines AA

    . Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women. Climacteric 2013;16:338–46.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Stuenkel CA,
    2. Davis SR,
    3. Gompel A,
    4. et al

    . Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015;100:3975–4011.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Woods NF,
    2. Mitchell ES,
    3. Landis C

    . Anxiety, hormonal changes, and vasomotor symptoms during the menopause transition. Menopause 2005;12:242–5.

    OpenUrlPubMed
21. 21.↵
    1. Politi MC,
    2. Schleinitz MD,
    3. Col NF

    . Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. J Gen Intern Med 2008;23:1507–13.

    OpenUrlCrossRefPubMedWeb of Science
22. 22.↵
    Society TNAM. Menopause Practice: A Clinician's Guide 6th ed 2019.
23. 23.↵
    1. Marjoribanks J,
    2. Farquhar C,
    3. Roberts H,
    4. Lethaby A,
    5. Lee J

    . Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2017;1:CD004143.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Del Carmen MG,
    2. Rice LW

    . Management of menopausal symptoms in women with gynecologic cancers. Gynecol Oncol 2017;146:427–35.

    OpenUrlPubMed
25. 25.↵
    1. Harris BS,
    2. Bishop KC,
    3. Kuller JA,
    4. et al

    . Hormonal management of menopausal symptoms in women with a history of gynecologic malignancy. Menopause 2020;27:243–8.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Marchetti C,
    2. De Felice F,
    3. Boccia S,
    4. et al

    . Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis. Crit Rev Oncol Hematol 2018;132:111–5.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Rossouw JE,
    2. Anderson GL,
    3. Prentice RL

    , Writing Group for the Women's Health Initiative Investigatorset al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33.

    OpenUrlCrossRefPubMedWeb of Science
28. 28.↵
    1. Farquhar C,
    2. Marjoribanks J,
    3. Lethaby A,
    4. Suckling JA,
    5. Lamberts Q

    . Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2009;CD004143.
29. 29.↵
    1. Olié V,
    2. Canonico M,
    3. Scarabin PY

    . Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr Opin Hematol 2010;17:457–63.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Mohammed K,
    2. Abu Dabrh AM,
    3. Benkhadra K,
    4. et al

    . Oral vs transdermal estrogen therapy and vascular events: a systematic review and meta-analysis. J Clin Endocrinol Metab 2015;100:4012–20.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Cho L,
    2. Kaunitz AM,
    3. Faubion SS

    , ACC CVD in Women Committeeet al. Rethinking menopausal hormone therapy: for whom, what, when, and how long? Circulation 2023;147:597–610.

    OpenUrlCrossRefPubMed
32. 32.↵
    1. Sobel TH,
    2. Shen W

    . Transdermal estrogen therapy in menopausal women at increased risk for thrombotic events: a scoping review. Menopause 2022;29:483–90.

    OpenUrlCrossRefPubMed
33. 33.
    1. Hickey M,
    2. Szabo RA,
    3. Hunter MS

    . Non-hormonal treatments for menopausal symptoms. BMJ 2017;359:j5101.

    OpenUrlFREE Full Text
34. 34.↵
    1. Hill DA,
    2. Crider M,
    3. Hill SR

    . Hormone therapy and other treatments for symptoms of menopause. Am Fam Physician 2016;94:884–9.

    OpenUrlPubMed
35. 35.↵
    “The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. Menopause 2023;30:573–90.

    OpenUrlCrossRefPubMed
36. 36.↵
    1. Shams T,
    2. Firwana B,
    3. Habib F,
    4. et al

    . SSRIs for hot flashes: a systematic review and metaanalysis of randomized trials. J Gen Intern Med 2014;29:204–13.

    OpenUrlCrossRefPubMed
37. 37.↵
    1. Wei D,
    2. Chen Y,
    3. Wu C,
    4. et al

    . Effect and safety of paroxetine for vasomotor symptoms: systematic review and meta-analysis. BJOG 2016;123:1735–43.

    OpenUrlPubMed
38. 38.↵
    1. Yoon SH,
    2. Lee JY,
    3. Lee C,
    4. Lee H,
    5. Kim SN

    . Gabapentin for the treatment of hot flushes in menopause: a meta-analysis. Menopause 2020;27:485–93.

    OpenUrlPubMed
39. 39.↵
    1. Shan D,
    2. Zou L,
    3. Liu X,
    4. Shen Y,
    5. Cai Y,
    6. Zhang J

    . Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms: a systematic review and meta-analysis. Am J Obstet Gynecol 2020;222:564–79.e12.

    OpenUrlPubMed
40. 40.↵
    1. Azizi M,
    2. Khani S,
    3. Kamali M,
    4. Elyasi F

    . The efficacy and safety of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in the treatment of menopausal hot flashes: a systematic review of clinical trials. Iran J Med Sci 2022;47:173–93.

    OpenUrlPubMed
41. 41.
    1. Bonga KN,
    2. Mishra A,
    3. Maiti R,
    4. Padhy BM,
    5. Meher BR,
    6. Srinivasan A

    . Efficacy and safety of fezolinetant for the treatment of menopause-associated vasomotor symptoms: a meta-analysis. Obstet Gynecol 2024;143:393–402.

    OpenUrlPubMed
42. 42.↵
    1. Lederman S,
    2. Ottery FD,
    3. Cano A,
    4. et al

    . Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet 2023;401:1091–102.

    OpenUrlCrossRefPubMed
43. 43.↵
    1. Pinkerton JV,
    2. Redick DL,
    3. Homewood LN,
    4. Kaunitz AM

    . Neurokinin receptor antagonist, fezolinetant, for treatment of menopausal vasomotor symptoms. J Clin Endocrinol Metab 2023;108:e1448–e1449.

    OpenUrlPubMed
44. 44.
    1. Ramaswami R,
    2. Villarreal MD,
    3. Pitta DM,
    4. Carpenter JS,
    5. Stebbing J,
    6. Kalesan B

    . Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 2015;152:231–7.

    OpenUrlCrossRefPubMed
45. 45.↵
    1. Umland EM,
    2. Falconieri L

    . Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine. Int J Womens Health 2012;4:305–19.

    OpenUrlCrossRefPubMed
46. 46.
    1. Daley A,
    2. Stokes-Lampard H,
    3. Thomas A,
    4. MacArthur C

    . Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2014;2014:CD006108.

    OpenUrlPubMed
47. 47.↵
    1. Lethaby A,
    2. Marjoribanks J,
    3. Kronenberg F,
    4. Roberts H,
    5. Eden J,
    6. Brown J

    . Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev 2013;2013:CD001395.

    OpenUrlPubMed
48. 48.
    NIH. Dietary Supplements: What You Need to Know. Fact Sheet for Consumers. Dietary Supplement Fact Sheets 2023.
49. 49.
    1. Sarri G,
    2. Pedder H,
    3. Dias S,
    4. Guo Y,
    5. Lumsden MA

    . Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause. BJOG 2017;124:1514–23.

    OpenUrlPubMed
50. 50.
    1. Castelo-Branco C,
    2. Gambacciani M,
    3. Cano A,
    4. et al

    . Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms - an update on the evidence. Climacteric 2021;24:109–19.

    OpenUrlPubMed
51. 51.
    1. Leach MJ,
    2. Moore V

    . Black cohosh for menopausal symptoms. Cochrane Database Syst Rev 2012;2012:CD007244.

    OpenUrlPubMed
52. 52.
    1. Garita-Hernandez M,
    2. Calzado MA,
    3. Caballero FJ,
    4. et al

    . The growth inhibitory activity of the Cimicifuga racemosa extract Ze 450 is mediated through estrogen and progesterone receptors-independent pathways. Planta Med 2006;72:317–23.

    OpenUrlPubMed
53. 53.
    1. Sinreih M,
    2. Gregorič K,
    3. Gajser K,
    4. Rižner TL

    . Physiological concentrations of Cimicifuga racemosa extract do not affect expression of genes involved in estrogen biosynthesis and action in endometrial and ovarian cell lines. Biomolecules. 2022;12.
54. 54.
    1. Seidlova-Wuttke D,
    2. Hesse O,
    3. Jarry H,
    4. et al

    . Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol- 17beta. Eur J Endocrinol 2003;149:351–62.

    OpenUrlAbstract
55. 55.
    1. Kaszkin-Bettag M,
    2. Ventskovskiy BM,
    3. Solskyy S,
    4. et al

    . Confirmation of the efficacy of ERr 731 in perimenopausal women with menopausal symptoms. Altern Ther Health Med 2009;15:24–34.

    OpenUrlPubMed
56. 56.
    1. Zeidabadi A,
    2. Yazdanpanahi Z,
    3. Dabbaghmanesh MH,
    4. Sasani MR,
    5. Emamghoreishi M,
    6. Akbarzadeh M

    . The effect of Salvia officinalis extract on symptoms of flushing, night sweat, sleep disorders, and score of forgetfulness in postmenopausal women. J Fam Med Prim Care 2020;9:1086–92.

    OpenUrl
57. 57.
    1. Wilfried D,
    2. Nina CDG,
    3. Silvia B

    . Effectiveness of Menosan®. Heliyon 2021;7:e05910.

    OpenUrl
58. 58.
    1. Millet Y,
    2. Jouglard J,
    3. Steinmetz MD,
    4. Tognetti P,
    5. Joanny P,
    6. Arditti J

    . Toxicity of some essential plant oils. Clinical and experimental study. Clin Toxicol 1981;18:1485–98.

    OpenUrlCrossRefPubMedWeb of Science
59. 59.
    1. Chen MN,
    2. Lin CC,
    3. Liu CF

    . Efficacy of phytoestrogens for menopausal symptoms: a meta-analysis and systematic review. Climacteric 2015;18:260–9.

    OpenUrlPubMed
60. 60.
    1. Franco OH,
    2. Chowdhury R,
    3. Troup J,
    4. et al

    . Use of plant-based therapies and menopausal symptoms: a systematic review and meta-analysis. JAMA 2016;315:2554–63.

    OpenUrlCrossRefPubMed
61. 61.
    1. Williamson-Hughes PS,
    2. Flickinger BD,
    3. Messina MJ,
    4. Empie MW

    . Isoflavone supplements containing predominantly genistein reduce hot flash symptoms: a critical review of published studies. Menopause 2006;13:831–9.

    OpenUrlCrossRefPubMedWeb of Science
62. 62.
    OSU. Soy Isoflavones. Oregon State University; 2014. Available at: https://lpi.oregonstate.edu/mic/dietary-factors/phytochemicals/soy-isoflavones.
63. 63.
    1. Shakeri F,
    2. Taavoni S,
    3. Goushegir A,
    4. Haghani H

    . Effectiveness of red clover in alleviating menopausal symptoms: a 12-week randomized, controlled trial. Climacteric 2015;18:568–73.

    OpenUrlCrossRefPubMed
64. 64.
    1. Myers SP,
    2. Vigar V

    . Effects of a standardised extract of Trifolium pratense (Promensil) at a dosage of 80mg in the treatment of menopausal hot flushes: A systematic review and meta analysis. Phytomedicine 2017;24:141–7.

    OpenUrlPubMed
65. 65.
    1. Chattha R,
    2. Nagarathna R,
    3. Padmalatha V,
    4. Nagendra HR

    . Effect of yoga on cognitive functions in climacteric syndrome: a randomised control study. BJOG 2008;115:991–1000.

    OpenUrlCrossRefPubMed
66. 66.
    1. Cramer H,
    2. Peng W,
    3. Lauche R

    . Yoga for menopausal symptoms-a systematic review and meta-analysis. Maturitas 2018;109:13–25.

    OpenUrlPubMed
67. 67.
    1. Dodin S,
    2. Blanchet C,
    3. Marc I,
    4. et al

    . Acupuncture for menopausal hot flushes. Cochrane Database Syst Rev 2013;2013:CD007410.

    OpenUrlPubMed
68. 68.
    1. Befus D,
    2. Coeytaux RR,
    3. Goldstein KM,
    4. et al

    . Management of menopause symptoms with acupuncture: an umbrella systematic review and meta-analysis. J Altern Complement Med 2018;24:314–23.

    OpenUrlPubMed
69. 69.
    1. Elkins GR,
    2. Fisher WI,
    3. Johnson AK,
    4. Carpenter JS,
    5. Keith TZ

    . Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial. Menopause 2013;20:291–8.

    OpenUrlCrossRefPubMed
70. 70.
    1. van Driel CM,
    2. Stuursma A,
    3. Schroevers MJ,
    4. Mourits MJ,
    5. de Bock GH

    . Mindfulness, cognitive behavioural and behaviour-based therapy for natural and treatment-induced menopausal symptoms: a systematic review and meta-analysis. BJOG 2019;126:330–9.

    OpenUrlPubMed
71. 71.
    1. Green SM,
    2. Donegan E,
    3. Frey BN,
    4. et al

    . Cognitive behavior therapy for menopausal symptoms (CBT-Meno): a randomized controlled trial. Menopause 2019;26:972–80.

    OpenUrlCrossRefPubMed